Stockscreener 앱 받기
46.58
1.37%
0.63
시간 외 거래:
46.57
-0.010
-0.02%
전일 마감가:
$45.95
열려 있는:
$45.64
하루 거래량:
2.50M
Relative Volume:
0.82
시가총액:
$8.84B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-19.33
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-1.67%
1개월 성능:
+7.85%
6개월 성능:
+46.25%
1년 성능:
+90.28%
1일 변동 폭
$45.40
$47.24
1주일 범위
$42.09
$49.77
52주 변동 폭
$21.72
$49.77
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
46.58 | 8.57B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Scotiabank Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $57 to $62 - 富途牛牛
BridgeBio Pharma Shares Plunge 8.94% as $620M Trading Volume Surges 126.94% to Top 500-Stock Volume Rankings Despite $110M Revenue Growth and 3,751 Prescriptions for Attruby - AInvest
BridgeBio Pharma 2025 Q2 Earnings Deepened Losses Amid Record Revenue Growth - AInvest
BridgeBio Earnings: Attruby Ramp Supports Long-Term Growth Outlook - Morningstar
BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales - Investing.com Canada
As competition heats up, BridgeBio's Attruby sales underwhelm Wall Street despite growth - Endpoints News
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam - insights.citeline.com
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - The Manila Times
BridgeBio Pharma stock price target raised to $61 by Oppenheimer - Investing.com Nigeria
Helix Acquisition Corp. II Retains Over 60% of Trust Account After Redemptions in BridgeBio Oncology Therapeutics Deal, Securing $382 Million in Gross Proceeds. - AInvest
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BridgeBio Pharma Beat Estimates With Strong Q2 Revenue Growth - Finimize
BridgeBio Pharma Plunges 12.21% Amid Factory Orders Drop - AInvest
BridgeBio Pharma: Q2 Earnings Snapshot - New Haven Register
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... By GuruFocus - Investing.com Canada
BridgeBio Pharma Reports Strong Q2 2025 Results - TipRanks
Transcript : BridgeBio Pharma, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 By Investing.com - Investing.com South Africa
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 - Investing.com
BridgeBio Pharma earnings missed by $0.20, revenue topped estimates - Investing.com South Africa
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
Why BridgeBio Pharma's Q2 Revenue Beat Signals a Catalyst for Outperformance - AInvest
BridgeBio Earnings: Attruby Sales Surge to $71M with Major Phase 3 Results Coming Fall 2025 - Stock Titan
BridgeBio Pharma stock hits 52-week high at 48.74 USD - Investing.com
BridgeBio Pharma stock hits 52-week high at 48.74 USD By Investing.com - Investing.com Nigeria
BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What makes BridgeBio Pharma Inc. stock price move sharplySkyrocketing returns - Jammu Links News
Is BridgeBio Pharma Inc. a growth stock or a value stockMaximize your returns with smart trade entries - Jammu Links News
How strong is BridgeBio Pharma Inc. company’s balance sheetConsistently high returns - Jammu Links News
Is it the right time to buy BridgeBio Pharma Inc. stockFree Stock Movement Tracking - Jammu Links News
How does BridgeBio Pharma Inc. generate profit in a changing economyBeginner Investor Watchlist For 2025 - Jammu Links News
Can volume confirm reversal in BridgeBio Pharma Inc.AI Forecast for Trending Stocks Indicates Upside - metal.it
Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma Inc. stock volume spike explainedPotential Breakout Stock List Published This Week - metal.it
Raymond James assumes coverage on BridgeBio stock with Outperform rating - Investing.com Canada
BridgeBio Pharma Inc. Breaks Losing Streak — Is the Trend ReversingEarly Entry Tips With Low Risk Zone Shared - metal.it
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Cantor Fitzgerald maintains BridgeBio stock rating, sees $3B+ potential By Investing.com - Investing.com Canada
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN
BridgeBio Pharma Inc. Hits Oversold Level on RSI IndicatorEntry Alert Based on Volume Spikes Detected - metal.it
Moving Average Crossover Confirms Uptrend in BridgeBio Pharma Inc.Stock Screener With Smart Filters Highlights Top Picks - metal.it
What is BridgeBio Pharma Inc. company’s growth strategyAchieve breakthrough performance with smart picks - Jammu Links News
Published on: 2025-07-28 13:33:40 - metal.it
Will BridgeBio Pharma Inc. stock benefit from interest rate changesWeekly Chart Analysis With Entry Advice Provided - metal.it
Why BridgeBio Pharma Inc. stock attracts strong analyst attentionLow Volatility Stable Growth Picks Rank High - metal.it
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):